secwatch.observer — SEC 8-K summary
======================================

Issuer:     NANOVIRICIDES, INC. (NNVC)
CIK:        0001379006
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001104659-23-040296
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoViricides licenses COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer for India
--------------------------------------------------------------------------------

- Exclusive license for development and commercialization in India; Karveer to sponsor Phase I and II clinical trials.
- NanoViricides reimburses all direct/indirect trial costs plus a 30% fee; Karveer pays 70% of invoiced commercial sales to NanoViricides.
- No minimum royalties or license maintenance fees; term continues as long as Karveer uses NanoViricides' proprietary technologies.
- NanoViricides retains full rights to clinical data for use outside India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/0001104659-23-040296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/tm2311179d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-040296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer